Mechanisms of cancer-associated thrombosis

A State-of-the-Art lecture titled “Mechanisms of cancer-associated thrombosis” was presented at the ISTH Congress in 2022. Patients with cancer have a 4-fold to 9-fold increased risk of venous thromboembolism (VTE) compared with the general population, so-called cancer-associated thrombosis (CAT). Different rates of VTE are observed in different types of cancer, suggesting that there are cancer-type specific mechanisms of CAT. We will discuss 4 pathways of CAT: tissue factor, podoplanin, neutrophil extracellular traps, and plasminogen activator inhibitor-1. In addition, specific gene mutations may increase the rate of CAT in some cancer types. A better understanding of these pathways may lead to the identification of biomarkers that can identify patients at risk for VTE and allow the development of new treatments to prevent CAT. Finally, we summarize relevant new data on this topic presented at the 2022 ISTH Congress.

• Publication year

  2023

• Venue

  Research and Practice in Thrombosis and Haemostasis

• Publication date

  2023-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.rpth.2023.100123PMID 37122533PMCID 10139954
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neutrophil extracellular traps promote cancer-associated inflammation and myocardial stress

  2022cited by this paper
• Circulating Tumor Cells and Cancer-Associated Venous Thrombosis: A Missing Link.

  2022cited by this paper
• Neutrophil extracellular traps participate in the development of cancer-associated thrombosis in patients with gastric cancer

  2022cited by this paper
• Tissue factor and its procoagulant activity on cancer‐associated thromboembolism in pancreatic cancer: Comment by Mackman et al.

  2022cited by this paper
• Histopathological Features of Cancer-Associated Venous Thromboembolism: Presence of Intrathrombus Cancer Cells and Prothrombotic Factors

  2022cited by this paper
• Neutrophil extracellular traps in the pathology of cancer and other inflammatory diseases.

  2022cited by this paper
• Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles.

  2021influential reference
• Prognostic value of circulating markers of neutrophil activation, neutrophil extracellular traps, coagulation and fibrinolysis in patients with terminal cancer

  2021cited by this paper
• American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer.

  2021cited by this paper
• Blocking podoplanin inhibits platelet activation and decreases cancer-associated venous thrombosis.

  2021cited by this paper
• Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer.

  2021cited by this paper
• The incidence of cancer-associated thrombosis is increasing over time

  2021cited by this paper
• Podoplanin promotes tumor growth, platelet aggregation, and venous thrombosis in murine models of ovarian cancer

  2021cited by this paper
• Role of tissue-factor bearing extracellular vesicles released from ovarian cancer cells in platelet aggregation in vitro and venous thrombosis in mice

  2021cited by this paper
• Role of neutrophil extracellular traps in radiation resistance of invasive bladder cancer

  2021cited by this paper
• ELISA detection of MPO-DNA complexes in human plasma is error-prone and yields limited information on neutrophil extracellular traps formed in vivo

  2021cited by this paper
• Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927-974.

  2021cited by this paper
• Heterogenous presence of neutrophil extracellular traps in human solid tumours is partially dependent on IL‐8

  2021cited by this paper
• Cathepsin C promotes breast cancer lung metastasis by modulating neutrophil infiltration and neutrophil extracellular trap formation.

  2020cited by this paper
• Genomic Profiling Identifies Somatic Mutations Predicting Thromboembolic Risk in Patients with Solid Tumors

  2020cited by this paper
• Plasminogen activator inhibitor-2 (PAI-2) overexpression supports bladder cancer development in PAI-1 knockout mice in N-butyl-N- (4-hydroxybutyl)-nitrosamine- induced bladder cancer mouse model

  2020cited by this paper
• Effect of chemotherapy and longitudinal analysis of circulating extracellular vesicle tissue factor activity in patients with pancreatic and colorectal cancer

  2020cited by this paper
• Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in Non-Small Cell Lung Cancer.

  2020cited by this paper
• Quantification of citrullinated histones: Development of an improved assay to reliably quantify nucleosomal H3Cit in human plasma

  2020cited by this paper
• Interleukin-17–induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer

  2020cited by this paper
• Cancer associated thrombosis and mortality in patients with cancer stratified by khorana score risk levels

  2020cited by this paper
• Venous thromboembolism in cancer patients: a population-based cohort study.

  2020cited by this paper
• A new hybrid immunocapture bioassay with improved reproducibility to measure tissue factor-dependent procoagulant activity of microvesicles from body fluids.

  2020cited by this paper
• Anaplastic lymphoma kinase rearrangement may increase the incidence of venous thromboembolism by increasing tissue factor expression in advanced lung adenocarcinoma

  2020cited by this paper
• Risk of thromboembolism in patients with ALK‐ and EGFR‐mutant lung cancer: A cohort study

  2020cited by this paper
• Neutrophils and neutrophil extracellular traps enhance venous thrombosis in mice bearing human pancreatic tumors

  2019cited by this paper
• Citrullinated histone H3, a biomarker for neutrophil extracellular trap formation, predicts the risk of mortality in patients with cancer

  2019cited by this paper
• Contact System Activation and Neutrophil Extracellular Trap Markers: Risk Factors for Portal Vein Thrombosis in Patients With Hepatocellular Carcinoma

  2019cited by this paper
• Podoplanin promotes cancer-associated thrombosis and contributes to the unfavorable overall survival in an ectopic xenograft mouse model of oral cancer

  2019cited by this paper
• Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin.

  2019cited by this paper
• Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin.

  2019influential reference
• IL-1β Blockade Attenuates Thrombosis in a Neutrophil Extracellular Trap-Dependent Breast Cancer Model

  2019cited by this paper
• Increasing the sensitivity of the human microvesicle tissue factor activity assay.

  2019cited by this paper
• Circulating DNAs, a Marker of Neutrophil Extracellular Traposis and Cancer-Related Stroke.

  2019cited by this paper
• High circulating levels of MPO-DNA are associated with thrombosis in patients with MPN

  2019cited by this paper
• Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients

  2018cited by this paper
• Tissue Factor: An Essential Mediator of Hemostasis and Trigger of Thrombosis

  2018cited by this paper
• Thromboembolism in Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer.

  2018cited by this paper
• Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: A sub-study of RASTEN - A randomized trial with low molecular weight heparin

  2018cited by this paper
• Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism

  2018cited by this paper
• Incidence and risk factors for venous thromboembolism in patients with pretreated advanced pancreatic carcinoma

  2018cited by this paper
• Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms

  2018cited by this paper
• Comparison of microvesicle tissue factor activity in non-cancer severely ill patients and cancer patients.

  2018cited by this paper
• Distinct Pathogenesis of Pancreatic Cancer Microvesicle–Associated Venous Thrombosis Identifies New Antithrombotic Targets In Vivo

  2018cited by this paper
• Single cell coagulomes as constituents of the oncogene-driven coagulant phenotype in brain tumours.

  2018cited by this paper
• Citrullinated histone H3 as a novel prognostic blood marker in patients with advanced cancer

  2018cited by this paper
• Cancer-associated pathways and biomarkers of venous thrombosis.

  2017cited by this paper
• C‐type lectin‐like receptor 2 promotes hematogenous tumor metastasis and prothrombotic state in tumor‐bearing mice

  2017cited by this paper
• Arteriosclerosis, Thrombosis, and Vascular Biology.

  2017influential reference
• Mouse models of cancer-associated thrombosis.

  2017cited by this paper
• Human pancreatic tumors grown in mice release tissue factor‐positive microvesicles that increase venous clot size

  2017cited by this paper
• Tumor-Derived Exosomes Induce the Formation of Neutrophil Extracellular Traps: Implications For The Establishment of Cancer-Associated Thrombosis

  2017cited by this paper
• Neutrophil extracellular traps are increased in cancer patients but does not associate with venous thrombosis.

  2017cited by this paper
• Evaluation of venous thrombosis and tissue factor in epithelial ovarian cancer.

  2017cited by this paper
• ALK‐Rearranged Non–Small‐Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism

  2017cited by this paper
• Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism.

  2017cited by this paper
• Mutant IDH1 and thrombosis in gliomas

  2016cited by this paper
• Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma

  2016cited by this paper
• Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.

  2016cited by this paper
• NETosis promotes cancer-associated arterial microthrombosis presenting as ischemic stroke with troponin elevation.

  2016cited by this paper
• Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs)

  2016cited by this paper
• The origin and concentration of circulating microparticles differ according to cancer type and evolution: A prospective single‐center study

  2016cited by this paper
• Tissue factor-bearing microparticles and CA19.9: two players in pancreatic cancer-associated thrombosis?

  2016cited by this paper
• Tissue factor–positive tumor microvesicles activate platelets and enhance thrombosis in mice

  2016cited by this paper
• Expression of Tissue Factor in Epithelial Ovarian Carcinoma Is Involved in the Development of Venous Thromboembolism

  2016cited by this paper
• Tissue factor expressed by circulating cancer cell‐derived microparticles drastically increases the incidence of deep vein thrombosis in mice

  2015cited by this paper
• Neutrophil Extracellular Traps Accumulate in Peripheral Blood Vessels and Compromise Organ Function in Tumor-Bearing Animals.

  2015cited by this paper
• Incidence of Ct scan-detected pulmonary embolism in patients with oncogene-addicted, advanced lung adenocarcinoma.

  2015cited by this paper
• Bevacizumab promotes venous thromboembolism through the induction of PAI-1 in a mouse xenograft model of human lung carcinoma

  2015cited by this paper
• First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer.

  2015cited by this paper
• Procoagulant role of neutrophil extracellular traps in patients with gastric cancer.

  2015cited by this paper
• Risk factors and prognostic impact of venous thromboembolism in Asian patients with non-small cell lung cancer

  2014cited by this paper
• Active PAI-1 as marker for venous thromboembolism: case-control study using a comprehensive panel of PAI-1 and TAFI assays.

  2014cited by this paper
• Plasma plasminogen activator inhibitor-1 (PAI-1) levels in breast cancer - relationship with clinical outcome.

  2014cited by this paper
• First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

  2014cited by this paper
• Ceritinib in ALK-rearranged non-small-cell lung cancer.

  2014cited by this paper
• Mutant IDH1 inhibits PI3K/Akt signaling in human glioma

  2014cited by this paper
• Plasminogen activator‐1 overexpression decreases experimental postthrombotic vein wall fibrosis by a non‐vitronectin‐dependent mechanism

  2014cited by this paper
• Ceritinib in ALK-rearranged non-small-cell lung cancer.

  2014cited by this paper
• Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas.

  2014cited by this paper
• Evaluation of a new commercial assay to measure microparticle tissue factor activity in plasma: communication from the SSC of the ISTH

  2014cited by this paper
• Epidemiology of cancer-associated venous thrombosis.

  2013cited by this paper
• Biomarkers for prediction of venous thromboembolism in cancer.

  2013cited by this paper
• Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

  2013cited by this paper
• Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers.

  2013influential reference
• Coagulation‐related gene expression profile in glioblastoma is defined by molecular disease subtype

  2013cited by this paper
• Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer- relationship with venous thrombosis risk.

  2013cited by this paper
• Microparticle‐associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features

  2013cited by this paper
• Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer.

  2012influential reference
• Microparticle-associated tissue factor activity measured with the Zymuphen MP-TF kit and the calibrated automated thrombogram assay

  2012cited by this paper
• Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis

  2012influential reference
• Pre-analytical and analytical variables affecting the measurement of plasma-derived microparticle tissue factor activity.

  2012cited by this paper
• Coagulation activation and microparticle-associated coagulant activity in cancer patients

  2012cited by this paper
• Prevention and treatment of venous thromboembolism in patients with cancer

  2012cited by this paper
• Microparticle‐associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients

  2012influential reference

• CWRNNet: A deep learning approach for embryo development stage classification using microscopic images

  2026cites this paper
• Peri-procedural anticoagulation management for central venous catheter insertion in persons with cancer.

  2026cites this paper
• Pulmonary origin and risk assessment of cancer-associated thrombosis

  2026cites this paper
• Coagulation parameters in gastrointestinal cancer patients with venous thromboembolism.

  2026cites this paper
• Perioperative laboratory profiles predict complications after extensive head and neck reconstruction: a proof-of-concept study

  2026cites this paper
• Extracellular vesicles from the lung pro-thrombotic niche drive cancer-associated thrombosis and metastasis via integrin beta 2.

  2025cites this paper
• Histological differences among thrombi in thrombotic diseases

  2025cites this paper
• Neutrophil Extracellular Traps: At the Interface of Thrombosis and Comorbidities

  2025cites this paper
• Activated FXI-antithrombin and thrombin-antithrombin complexes in the prediction of venous thromboembolism and mortality in non-small cell lung cancer patients.

  2025cites this paper
• Tissue factor, factor VIII and IX in microvesicle-induced thrombosis and tumor growth of pancreatic cancer

  2025cites this paper
• Direct Oral Anticoagulants Are Comparable to Low Molecular Weight Heparin at Sustaining the Circulating Extracellular Vesicle and Inflammatory Profiles of Cancer Associated Thrombosis Patients: An Observational Pilot Study

  2025cites this paper
• Antithrombotic therapy for secondary stroke prevention in patients with cancer: a systematic review and network meta-analysis

  2025cites this paper
• Comparative evaluation of anticoagulant prophylaxis regimens in patients with malignant tumors of the pelvic organs in the perioperative period

  2025cites this paper
• Unravelling the role of TET2 in venous thromboembolism: insights into mechanisms and therapeutic implications

  2025cites this paper
• Coagulation and Fibrinolysis Profiles in Mouse Breast Cancer 4T1 Tumor-Bearing Mice: A Characterization of Neutrophil-Associated Prothrombotic States.

  2025cites this paper
• Cancer patients and ischemic stroke.

  2024cites this paper
• The pathogenesis of cancer-associated thrombosis

  2024cites this paper
• The regulation of cancer-associated thrombosis by podoplanin

  2024cites this paper
• Venous thrombosis and obesity: from clinical needs to therapeutic challenges

  2024cites this paper
• Chemotherapy alters thrombomodulin and factor VIIIc expression resulting in acquired activated protein C resistance and enhanced thrombin generation in cancer associated thrombosis.

  2024cites this paper
• Research progress on venous thrombosis development in patients with malignant tumors

  2024cites this paper
• Unprovoked venous thromboembolism recurrence and arterial embolism revealing lung cancer: a case report

  2024influential citation
• Intrathrombus cancer cells and expression of prothrombotic factors in cancer-associated venous thromboembolism

  2024cites this paper
• Using heart rate variability to evaluate the association between the autonomic nervous system and coagulation function in patients with endometrial cancer

  2024cites this paper
• Paclitaxel and Vinblastine Increase Plasminogen Activator Inhibitor-1 Production in Human Breast Cancer MCF-7 Cells but Not MDA-MB-231 Cells.

  2024cites this paper
• Cellular Components Contributing to the Development of Venous Thrombosis in Patients with Pancreatic Cancer

  2023cites this paper
• Relationship between Levels of Interleukin-6 and Tumour Necrosis Factor Alpha and Khorana Scores of Newly Diagnosed Ambulatory Cancer Patients

  2023cites this paper
• Tissue factor positive microparticles as a biomarker for increased risk of breast cancer-associated thrombosis: a mini review

  2023cites this paper